Dr. Matthew Hamill, MBChB, Ph.D

Claim this profile
Studies Human Immunodeficiency Virus Infection
Studies Syphilis
1 reported clinical trial
3 drugs studied

Clinical Trials Matthew Hamill, MBChB, Ph.D is currently running

Image of trial facility.

Point-of-Care Tests

for HIV Diagnosis

This study proposes to investigate the performance of existing and new technologies for HIV diagnosis, one of the key strategies for Ending the HIV Epidemic in the U.S. Current, Standard-of-Care (SOC) diagnostic techniques have extended turn-around-times (TATs) that result in loss of patients to follow up due to delays in laboratory procedures. In this scenario, patients that are at a high-risk for HIV have the potential to continue transmission, making it difficult to end the epidemic. Rapid, Point-of-Care (POC) HIV viral load (VL) testing alleviates this problem by reducing TATs that allow providers to test for HIV infection and link patients to antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) during the same clinical visit, and subsequently, suppress VL, prevent HIV infection, and reduce its transmission among high-risk populations. The study proposes that evaluating the performance of new and existing POC technologies is needed to provide updated information to HIV test providers operating in different populations and settings and improve linkage to HIV treatment and prevention services. The study hypothesizes that: A. Determining the performance characteristics of HIV POC tests will inform optimal testing strategies in different populations and settings B. The use of HIV RNA POC tests will improve linkage to HIV treatment and prevention services: i. Improve early diagnosis of HIV ii. Reduce the time to ART initiation iii. Facilitate timely and appropriate referral for prevention services
Recruiting1 award N/A7 criteria

More about Matthew Hamill, MBChB, Ph.D

Clinical Trial Related3 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Matthew Hamill, MBChB, Ph.D has experience with
  • Cepheid GeneXpert HIV-1 Qual POC HIV VL Test
  • DPP HIV-Syphilis Test System
  • OraQuick
Breakdown of trials Matthew Hamill, MBChB, Ph.D has run
Human Immunodeficiency Virus Infection

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Hamill, MBChB, Ph.D specialize in?
Matthew Hamill, MBChB, Ph.D focuses on Human Immunodeficiency Virus Infection and Syphilis. In particular, much of their work with Human Immunodeficiency Virus Infection has involved treating patients, or patients who are undergoing treatment.
Is Matthew Hamill, MBChB, Ph.D currently recruiting for clinical trials?
Yes, Matthew Hamill, MBChB, Ph.D is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Matthew Hamill, MBChB, Ph.D has studied deeply?
Yes, Matthew Hamill, MBChB, Ph.D has studied treatments such as Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick.
What is the best way to schedule an appointment with Matthew Hamill, MBChB, Ph.D?
Apply for one of the trials that Matthew Hamill, MBChB, Ph.D is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.